Table 1.
Patient Baseline Demographics and Disease Characteristics
| Treatment Arm, Age Group, Years | Both Treatment Arms, Age Group, Years |
|||||
|---|---|---|---|---|---|---|
| RPV | EFV | |||||
| <50 N=617 |
≥50 N=69 |
<50 N=625 |
≥50 N=57 |
<50 N=1242 |
≥50 N=126 |
|
| Median age, years (range) | 35 (18, 49) | 54 (50, 78) | 34 (19, 49) | 54 (50, 69) | 35 (18, 49) | 54 (50, 78) |
| Sex, n (%) | ||||||
| Female | 148 (24) | 20 (29) | 145 (23) | 18 (32) | 293 (24) | 38 (30) |
| Male | 469 (76) | 49 (71) | 480 (77) | 39 (68) | 949 (76) | 88 (70) |
| Race, n (%) | ||||||
| White | 375 (61) | 45 (65) | 375 (60) | 35 (61) | 750 (60) | 80 (64) |
| Black or African American | 145 (24) | 20 (29) | 140 (22) | 16 (28) | 285 (23) | 36 (29) |
| Asian | 74 (12) | 4 (6) | 94 (15) | 3 (5) | 168 (14) | 7 (6) |
| Othera | 7 (1) | 0 | 4 (1) | 3 (5) | 11 (1) | 3 (2) |
| Smoker | 227 (37) | 19 (28) | 210 (34) | 13 (23) | 437 (35) | 32 (25) |
| HCV,b n (%) | 44 (7) | 9 (13) | 50 (8) | 5 (9) | 94 (8) | 14 (11) |
| Clinical stage of HIV, n (%) | ||||||
| A | 442 (72) | 43 (62) | 436 (70) | 38 (67) | 878 (71) | 81 (64) |
| B | 146 (24) | 20 (29) | 154 (25) | 15 (26) | 300 (24) | 35 (28) |
| C | 29 (5) | 6 (9) | 35 (6) | 4 (7) | 64 (5) | 10 (8) |
| Median (range) duration of HIV disease at screening, years | 1 (0, 23) | 2 (0, 24) | 1 (0, 25) | 1 (0, 28) | 1 (0, 25) | 2 (0, 28) |
| N(t)RTI use, n (%) | 617 (100) | 69 (100) | 625 (100) | 57 (100) | 1242 (100) | 126 (100) |
| Abacavir sulfate with lamivudine | 38 (6.2) | 6 (8.7) | 34 (5.4) | 2 (3.5) | 72 (6) | 8 (6) |
| Emtricitabine and tenofovir disoproxil fumarate | 493 (79.9) | 59 (85.5) | 498 (79.7) | 49 (86.0) | 991 (80) | 108 (86) |
| Zidovudine with lamivudine | 101 (16.4) | 6 (8.7) | 98 (15.7) | 6 (10.5) | 199 (16) | 12 (10) |
| Median (range) CD4+ cell count at baseline, cells/mm3 | 253c (1, 888) | 220 (5, 879) | 261 (1, 919) | 257 (2, 1137) | 258d (1, 919) | 233 (2, 1137) |
| Mean (SD) HIV-1 RNA at baseline, log10 copies/mL | 4.9 (0.62) | 5.0 (0.64) | 4.9 (0.63) | 5.1 (0.56) | 4.9 (0.63) | 5.1 (0.61) |
RPV, rilpivirine; EFV, efavirenz; HCV, hepatitis C virus; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; SD, standard deviation.
aIncludes “not allowed to ask”; bHCV antibody positive or reactive; cN=616; dN=1241.